Atea Pharmaceuticals, Inc.AVIRNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank71
Studio
Year-over-Year Change

Price-to-earnings ratio

Latest
-1.84
↑ 97% vs avg
Percentile
P71
Within normal range
Streak
1 yr
Consecutive declineElevated
Average
-67.17
Historical baseline
PeriodValueYoY Change
2025-1.84-9.6%
2024-1.68+10.4%
2023-1.87+45.8%
2022-3.45-156.5%
20216.11+101.9%
2020-314.63-68.9%
2019-186.23-451.3%
2018-33.78-